Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
17 hedge funds and large institutions have $3.55M invested in Interpace Biosciences, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
37% less capital invested
Capital invested by funds: $5.66M → $3.55M (-$2.11M)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$55.8K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$17.2K |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$15.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$11.8K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$5.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$140K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$41.7K |
| 3 |
MPI
Mairs & Power Inc
St Paul,
Minnesota
|
-$40K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$9.28K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$5K |
IDXG Hedge Fund Activity: Q4 2019 in Review
17 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q4 2019, worth a combined $3.55M — down 37% from $5.66M a quarter earlier.
Fund positioning in IDXG was balanced in Q4 2019: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 5 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $55.8K. The largest seller was Stonepine Capital Management, cutting an estimated $140K.
- 17 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $3.55M of Interpace Biosciences, Inc. Common Stock stock for Q4 2019, down 37% quarter-over-quarter.
- 3 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q4 2019 and 3 closed out, a net change of 0 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q4 2019 was Virtu Financial, an estimated $55.8K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q4 2019 was Stonepine Capital Management, an estimated $140K sold.
Based on aggregated 13F filings for Q4 2019.